Orange Health Doubled Revenue. The Reported Loss Did Not Move.

The mechanism is a single line on the FY24 P&L: a deferred tax credit of ₹26.31 Cr. The company recognised additional deferred tax assets in FY24 on disallowances under Sections 40(a)(ia), 43B, and 40A(7) of the Income Tax Act, and the increase flowed through the tax expense line as a credit. The credit reduced FY24's pre-tax loss of ₹106.69 Cr down to a post-tax loss of ₹80.39 Cr.

FY25 did not carry a comparable tax-line entry through the P&L. The closing balance of deferred tax assets did grow during FY25, from ₹22.73 Cr to ₹49.05 Cr, but the increase did not appear as a P&L credit in the way it did in FY24. As a result, the FY25 reported loss is approximately equal to the operating loss before tax.

Translation: FY24's bottom line was lower than its operating performance. FY25's bottom line approximately matches its operating performance. Comparing the two as if they measured the same thing produces a misleading flat picture.

The auditor flags the ₹49.05 Cr deferred tax asset balance in an Emphasis of Matter, noting that recognition rests on management's confidence of future profits. Had the company reversed the deferred tax assets, the FY25 net worth and reported loss would each be adversely impacted by the same amount.

The capital structure is equity-only. There are no bank borrowings, no debentures, no compulsorily convertible instruments classified as debt. Every rupee of external capital sits in the securities premium reserve, which has grown from ₹264.4 Cr at March 31, 2024 to ₹394.8 Cr at March 31, 2025, an increase of ₹130.4 Cr. The prior year's increase was ₹124.3 Cr. The two-year total is ₹254.7 Cr of fresh equity raised.

Over the same two-year window, the auditor-disclosed cash loss totals ₹173 Cr (₹96.55 Cr in FY24 plus ₹76.45 Cr in FY25). Cumulative securities premium of ₹395 Cr exceeds cumulative losses of ₹179 Cr; the net of the two, plus a nominal share capital and a ₹7 Cr ESOP reserve, produces a positive net worth of ₹223 Cr.

The structural read: net worth is positive because each round arrives ahead of the year's burn. The operating model has not yet generated cash; the funding model has covered the gap. The two-year arithmetic shows raises (₹254 Cr) running about ₹82 Cr ahead of cash burn (₹173 Cr), which has built the ₹106 Cr of liquid balances on the books.

The auditor's Other Matter note states that the US parent Orchard Healthcare Inc. is merging into the Indian entity Orchard Healthcare Private Limited. The Inc. entity is the Transferor; the Pvt Ltd entity is the Transferee. Regulatory approvals were underway at the date of the audit report; completion is expected in Q3 of FY2025-26.

This is the reverse-flip or internalisation pattern. A startup with a foreign holding company brings its corporate domicile back to India, typically before a planned listing on Indian exchanges. The pattern carries tax cost (capital gains can apply at the shareholder level under certain structures) and is therefore deliberate.

Recent precedents include PhonePe (2022), Pine Labs (2024-25), and Razorpay (announced 2024). The audit does not state IPO intent explicitly; the filing simply notes the merger and the expected completion timeline. The closing accounting impact will be that the equity currently held at the US parent level will be reflected directly at the Indian entity, dissolving the holding-company layer.